Cyclacel Pharmaceuticals, Inc (CYCC) Dividend History

Company News

• CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

  Cyclacel Pharmaceuticals announced its Q1 2025 financial results, including a focus on the development of plogosertib and the deconsolidation of its UK subsidiary Cyclacel Limited. The company is exploring strategic alternatives to continue as a going concern, including a share exchange agreement with FITTERS Diversified Berhad.

  GlobeNewswire Inc.

  Featured Companies: CYCCP
• Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

  Cyclacel Pharmaceuticals announced a change in control and leadership, with Datuk Dr. Doris Wong Sing Ee becoming the new CEO and Kiu Cu Seng appointed as Executive Director, Secretary and Chief Financial Officer.

  GlobeNewswire Inc.

  Featured Companies: CYCCP
• Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

  Cyclacel Pharmaceuticals (CYCC) has seen a downtrend recently, but a hammer chart pattern and strong agreement among analysts on earnings estimates suggest a potential trend reversal. The article recommends buying the stock now.

  Benzinga

  Featured Companies: CYCCP
• Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

  NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS - Lengthens Patent Exclusivity to August 2040

  GlobeNewswire Inc.

  Featured Companies: CYCCP
• All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy

  Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  Zacks Investment Research